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Abstract
Individual genetic factors have long been suspected of playing a
major role in susceptibility to acute lung injury and acute respiratory
distress syndrome. Flores and colleagues evaluate the quality of
published studies testing the relationships between variation in
candidate genes and susceptibility to lung injury syndromes or
worsened outcome in patients with these conditions. Their results
demonstrate that while important advances have been made in this
area, attention should be paid to improving the methodology of
future studies in order to minimize the chances of publishing false-
positive results.
In the previous issue of Critical Care, Dr Flores and
colleagues travel down a familiar path [1]. Throughout the
history of medicine, physicians have wondered how to account
for the fact that individuals may respond so differently to
similar illnesses. Indeed, some of these relationships are
obvious – patients who do not receive antibiotics in a timely
fashion may progress rapidly from infection to septic shock
[2]; an older patient may be more likely to die than a younger,
healthier patient with the same illness [3]. Many a physician,
however, has been left to wonder why, given two relatively
similar patients with community-acquired pneumonia, one
patient may recover quickly with a standard course of
antibiotics while another patient develops catastrophic acute
lung injury with its attendant profound hypoxemia, multiorgan
failure, and high mortality rate.
The difference, of course, has long been thought to be in the
genes. That is, the disease phenotype of the patient results
from the sum of the complex interactions between the
environment and the patient’s genotype [4]. We are now at
the beginning of the second decade of the effort to better
define the role played by genetic variation in the patho-
genesis of acute lung injury and its most severe form, acute
respiratory distress syndrome [1].
The reasons for conducting such investigations are compell-
ing. By establishing the importance of genetic variation in
determining the final disease phenotype, it may be possible to
work backwards and identify the proteins that play a more
important role in disease pathogenesis. This might improve
our understanding of acute lung injury/acute respiratory
distress syndrome disease processes as well as generate
targets for therapeutic intervention. From the standpoint of
the clinician, knowing how the patient’s genotype will affect
the course of their illness might enable more accurate prog-
nostic assessment, or may even allow targeted therapeutic
interventions based on how the patient’s genotype predicts
they will respond [5].
As Flores and colleagues note, however, the road to these
anticipated outcomes has been bumpy. In their compre-
hensive exploration of the state of the literature, the authors
evaluated 29 original research studies that reported positive
associations between genetic variants and an altered level of
risk of developing acute lung injury/acute respiratory distress
syndrome, or positive associations with clinical outcomes [1].
They then sought to evaluate the quality of these studies
according to the recommendations of an expert panel [6].
This panel aimed to address a major issue that has plagued
genetic association studies: replication validity. Despite a
growing number of reported positive genotype–phenotype
associations across a variety of different diseases, a
substantial proportion of these associations lose significance
when tested in different patient populations, casting doubt on
whether the association truly exists or merely represents a
chance finding [7]. As part of this group’s recommendations,
they developed a list of consensus criteria for evaluating the
quality of studies that report novel associations. This is
relevant because the use of less robust methodology in initial
studies may hamper efforts to replicate their results [8]. The
panel’s criteria address a number of study design elements,
including power and sample size, precise definition of
phenotypes, careful steps to reduce confounding, appro-
priate selection of statistical methods, and close attention to
quality control.
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Using elements of these criteria as a guide, Flores and
colleagues discovered a few notable trends in the published
literature [1]. Most of the published studies reported positive
associations, in a total of 16 genes. Of these positive
associations, less than one-half were replicated in additional
populations. It is impossible to know how many of the
unreplicated results were not published because the asso-
ciations were found to be negative, or how many additional
genes showed negative associations that were not published.
Many studies had disappointing sample sizes, with a median
of around 100 to 200 patients depending on the study
design. In addition, most studies did not report power calcu-
lations. Flores and colleagues also point out heterogeneity in
the selection of a control group for case–control studies, with
a plurality of the studies selecting healthy subjects or
population-based control individuals.
These findings present a mixed picture – owing to the number
of studies with small sample sizes, a lack of replication studies,
absence of power calculations, and an unknown number of
unpublished negative studies, it is possible that many of these
associations were found merely due to chance. The choice of
control groups in some studies is also somewhat troubling. If
the goal is to study the impact of genotype on the risk of
developing lung injury, it seems counterintuitive to select
healthy patients or population-based control individuals as the
comparison group since these patients may in fact be
genetically susceptible and only require an appropriate
external stimulus to develop the disease.
Despite these potential flaws in published studies, the
authors also point to successes in the literature that can be
built upon – they suggest a need for studies with improved
initial quality (large sample sizes with adequate power,
selection of appropriate control groups, use of functional
surrogates to support associations with disease phenotype)
as well as the need for replication of initial findings. Future
studies should also employ newer technologies and strate-
gies such as large-scale multigene association studies, gene
expression studies [9], and biomarker/proteomic technolo-
gies [10] both for identification of novel candidate genes and
to provide additional data that support the relevance of
reported associations. A concerted effort by researchers and
journal editors should also be made to ensure that negative
initial and replication studies are published to reduce the
impact of publication bias. Finally, further studies in different
racial populations are needed.
A decade into the course of this work, we have taken only
small steps towards the goal. As Flores and colleagues show,
however, the foundation has been laid for ultimately
answering the crucial question posed by physicians – can we
take what we have learned about genotypes and apply it to
the care of the patient in front of us?
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